Form 4: Edgewise Therapeutics Director Jonathan C Fox Acquires Stock Options

Director Jonathan C Fox acquired 20,594 stock options in Edgewise Therapeutics, Inc. on June 10, 2024.

Summary

• On June 10, 2024, Jonathan C Fox, a director of Edgewise Therapeutics, Inc., acquired 20,594 stock options.
• The exercise price of these options is $17.13.
• The options vest on the earlier of June 10, 2025, or the business day prior to the 2025 annual meeting of stockholders.
• The options expire on June 10, 2034.
• Following the transaction, Fox directly owns 20,594 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It reflects a standard transaction and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting and expiration dates of the stock options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a transaction in company stock by an insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates